How does Edwards Lifesciences (EW) make money?

Edwards Lifesciences (EW) generates revenue primarily from Transcatheter Heart Valves, which accounted for 78% of total revenue in TTM through Q2 2026. The company reported $6.51B in revenue and converted 15.4% of it into net profit, equivalent to roughly $1B in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Edwards Lifesciences (EW)?

Edwards Lifesciences (EW) reported a gross profit margin of 78% in TTM through Q2 2026, equivalent to $5.08B in gross profit on $6.51B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Edwards Lifesciences (EW)?

Edwards Lifesciences (EW) reported an operating profit margin of 28.1% in TTM through Q2 2026, equivalent to $1.83B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Edwards Lifesciences (EW)?

Edwards Lifesciences (EW) reported a net profit margin of 15.4% in TTM through Q2 2026, equivalent to $1B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Edwards Lifesciences (EW) profitable?

Yes. Edwards Lifesciences (EW) reported $1B in net income for TTM through Q2 2026, with a net profit margin of 15.4%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does Edwards Lifesciences (EW) invest in research and development?

Edwards Lifesciences (EW) invested $1.09B in research and development during TTM through Q2 2026, roughly 16.7% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does Edwards Lifesciences (EW) spend on capital expenditures?

Edwards Lifesciences (EW) spent $269M on capital expenditures (CapEx) during TTM through Q2 2026, roughly 4.1% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Edwards Lifesciences (EW) generate?

Edwards Lifesciences (EW) generated $1.09B in free cash flow during TTM through Q2 2026, a free-cash-flow margin of 16.7%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of Edwards Lifesciences (EW)?

Edwards Lifesciences (EW) had an effective tax rate of 31% in TTM through Q2 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of Edwards Lifesciences (EW)?

Edwards Lifesciences (EW) reports revenue across 3 reportable product segments, led by Transcatheter Heart Valves at 78% of total revenue in TTM through Q2 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

How Edwards Lifesciences Makes Money: 2026 Visual Revenue Map

Edwards Lifesciences (EW) Income Statement Flow — TTM through Q2 2026

Calculated from the four most recent reported quarters, ending June 30, 2026 (reported June 30, 2026).

Edwards Lifesciences discloses geographic revenue only in annual filings. to view the full breakdown.

Edwards Lifesciences (EW) Revenue by Product Segment — TTM through Q2 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for Edwards Lifesciences (EW), TTM through Q2 2026.
Segment	Revenue (USD)	% of total
Transcatheter Heart Valves	$5.08B	78%
Surgical Heart Valve Therapy	$741M	11.4%
Transcatheter Mitral And Tricuspid Therapies	$690M	10.6%
Total	$6.51B	100%

Transcatheter Heart Valves$5.08B
Surgical Heart Valve Therapy$741M
Transcatheter Mitral And Tricuspid Therapies$690M
Total$6.51B

Revenue Breakdown — TTM through Q2 2026

In TTM through Q2 2026, Edwards Lifesciences (EW) reports revenue across 3 reportable product segments; the largest segment was Transcatheter Heart Valves at 78%, followed by Surgical Heart Valve Therapy (11.4%) and Transcatheter Mitral And Tricuspid Therapies (10.6%).

Frequently asked questions

Data & methodology

Edwards Lifesciences (EW) Key Financials

Charts, filings, and peer comparison for every metric

Trains Company Knowledge

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

EW Overview

Counters

Income Statement

Cash Flow

Capital Return

How this company returns cash to shareholders — buybacks, dividends, and stock splits.

Forecast & Valuation